Please try another search
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Name | Age | Since | Title |
---|---|---|---|
Shankar Musunuri | 60 | 2019 | Co-Founder, CEO & Chairman |
Carl D. Regillo | - | 2019 | Member of Retina Scientific Advisory Board |
Prabhavathi B. Fernandes | 75 | 2020 | Independent Director |
Ramesh Kumar | 68 | 2019 | Independent Director |
Bruce D. Forrest | 61 | 2020 | Vaccine Scientific Advisory Board Member |
Uday B. Kompella | 57 | 2019 | Co-founder & Independent Director |
Joseph W. Westphal | - | 2023 | Member of Business Advisory Board |
David S. Boyer | - | - | Member of Retina Scientific Advisory Board |
Satishchandran Chandrasekhar | - | 2020 | Vaccine Scientific Advisory Board Member |
Geeta Lalwani | - | - | Member of Retina Scientific Advisory Board |
Junge Zhang | 57 | 2019 | Independent Director |
Mark Pennesi | - | 2019 | Member of Retina Scientific Advisory Board |
Marna Cupp Whittington | 76 | 2022 | Independent Director |
Catherine J. Pachuk | 67 | 2020 | Vaccine Scientific Advisory Board Member |
David Fajgenbaum | - | 2020 | Vaccine Scientific Advisory Board Member |
Robert J. Smith | 63 | 2024 | Member of Business Advisory Board |
Connie R. Collingsworth | 65 | 2023 | Member of Business Advisory Board |
Susan Weiss | - | 2020 | Vaccine Scientific Advisory Board Member |
Kirsten M. Castillo | 50 | 2020 | Independent Director |
Patrick J. Toomey | 62 | 2023 | Member of Business Advisory Board |
Dennis C. Carey | 66 | 2023 | Member of Business Advisory Board |
Harvey Rubin | - | 2020 | Vaccine Scientific Advisory Board Member |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review